Anacor Pharmaceuticals Price Target Increased to $29.00 by Analysts at Wedbush (ANAC)
Analysts at Wedbush hoisted their price target on shares of Anacor Pharmaceuticals (NASDAQ:ANAC) to $29.00 in a research report issued to clients and investors on Friday, AnalystRatingsNetwork.com reports. Wedbush’s price target suggests a potential upside of 169.27% from the stock’s previous close.
Separately, analysts at Deutsche Bank raised their price target on shares of Anacor Pharmaceuticals from $11.00 to $20.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Anacor Pharmaceuticals (NASDAQ:ANAC) traded up 28.37% on Friday, hitting $13.825. 2,664,235 shares of the company’s stock traded hands. Anacor Pharmaceuticals has a 52 week low of $3.00 and a 52 week high of $12.63. The stock has a 50-day moving average of $10.67 and a 200-day moving average of $7.75. The company’s market cap is $560.7 million.
Anacor Pharmaceuticals (NASDAQ:ANAC) last announced its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.39) by $0.03. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter last year, the company posted ($0.47) earnings per share. Anacor Pharmaceuticals’s revenue was up 30.8% compared to the same quarter last year. Analysts expect that Anacor Pharmaceuticals will post $-1.67 EPS for the current fiscal year.
Anacor Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.